Content as a Compass: How to Use Content in Life Sciences ABM to Surface In-Market Buying Groups

In most B2B marketing programs, content serves a primary function: generating traffic and leads. A white paper or blog post goes live and organic search or ads drive traffic to the page. For gated content the hope is that contacts fill out a form and enter a nurture sequence. Content serves as a brand building and lead capture mechanism, and its value is measured in visits and form fills.

In a well-constructed life sciences ABM program, content does something more sophisticated than that. It functions as a diagnostic instrument and a way of identifying not just who is interested, but who is actively working on the problem your solution solves right now. When the right content is placed in front of the right audience, the pattern of who engages with it, when, and how deeply reveals whether a buying group is forming around a specific need at a target account. The content is not just attracting interest; it is surfacing intent.

This distinction matters because it changes how you think about content strategy, content deployment, and what you do with the data that content engagement generates. This post explains how to build and deploy content in a life sciences ABM program to do exactly that.

Why Content Works Differently in Life Sciences

The scientific training that makes life science buyers skeptical of promotional messaging also makes them genuinely receptive to content that helps them do their jobs better. A Translational Scientist working through the design of exploratory biomarker endpoints for a Phase 1 oncology program will engage seriously with a technically substantive white paper on relevant assay methods not necessarily because they are in a purchasing mindset, but because it is directly useful to their work. A Clinical Program Director navigating the operational complexities of transitioning an asset from Phase 1 to Phase 2 will read a case study documenting how a peer organization managed that transition, because it offers directly applicable intelligence. In the scenarios mentioned, evaluating vendors was not the primary objective for the scientist or clinical director when interacting with the material. However, their content engagement is an important signal - it indicates that they may be potential buyers within an active project window.

This dynamic is the foundation of content-driven ABM in life sciences: the content that attracts and engages your target audience is the same content that reveals where they are in their development process and what they are currently working on. A scientist reading an application note on a specific assay methodology is telling you something about their current research context. A program director downloading a guide on Phase 2 trial design is telling you something about the stage of their program. When those signals come from individuals at your target accounts - accounts which have been pre-selected based on the types of programs in development, upcoming trials, or funding signals - they are commercially meaningful in a way that generic web traffic never is.

The implication is that content in life sciences ABM needs to be genuinely useful to a scientifically trained audience: not just technically credentialed on the surface, but substantive enough to earn engagement from people who will evaluate it with real critical judgment. Promotional content dressed up with scientific language will not generate the engagement patterns that reveal buying intent. Genuine expertise, communicated clearly and practically, will.

Building the Content Matrix: Mapping Content to Persona and Funnel Stage

The planning tool that connects content strategy to ABM execution is the content matrix: a structured framework that maps content types and formats to each buying committee persona at each stage of the funnel. The output is a set of parallel content tracks, each designed for a different member of the buying committee, that together create the conditions for engagement across the full group.

At the top of the funnel (TOFU), the goal is to build broad awareness and surface accounts with relevant interest. Content here is educational and problem-focused rather than solution-focused. Blog posts that address common challenges in a specific development stage, industry guides on regulatory or scientific topics relevant to your target audience, and educational, pre-recorded webinars on topics at the intersection of your expertise and your audience's current priorities are all effective TOFU formats in life sciences. This content should be largely ungated — its purpose is to be found, consumed, and associated with your organization's expertise, not to generate form fills. The engagement signal it generates is traffic and repeat visitation, which when coming from target accounts is a meaningful early-stage indicator.

At the middle of the funnel (MOFU), content shifts from education to evaluation support. This is where gated assets earn their place: white papers with original data or analysis, benchmark reports on outsourcing outcomes or analytical performance, technical guides that help the audience solve a specific problem, and live webinars with genuine subject matter depth. These formats require a meaningful commitment from the reader; they take time to consume and offer enough value to justify providing contact information to access them. The form fill is the conversion event, and it captures not just a name and email address but a specific signal of intent: this person, at this company, is interested in this topic, at this level of depth.

Persona differentiation is especially important at this stage. A white paper on biomarker strategy speaks primarily to the scientific end-user and program lead. A case study on CRO delivery performance speaks to the program lead and procurement function. A vendor qualification guide speaks to procurement and legal. Running separate MOFU content tracks simultaneously, each targeted to a different persona, means that different members of the buying committee are engaging through channels calibrated to their concerns. And the engagement data you collect reflects the full committee, not just the scientific audience.

At the bottom of the funnel (BOFU), content supports active evaluation and decision-making. ROI or yearly total cost of operation calculators, detailed capability overviews, regulatory credential documentation, reference client case studies, and proposal-ready summaries are the formats that serve buyers who are close to a decision. This content should be available to engaged contacts without friction as the last thing you want when a buying group is actively evaluating is to put a barrier between them and the information they need to build the internal case for your solution.

Deploying Content Across ABM Channels

A content matrix is a planning tool. The commercial value comes from how that content is deployed across the channels that reach your target accounts and personas.

Programmatic advertising drives TOFU and MOFU content to all employees at target accounts. The targeting is account-level, and the primary purpose is to build brand familiarity and create the first touchpoints that move unknown contacts toward identified ones. Blog posts and educational guides work well as programmatic ad destinations since they are low-friction, yet high-value enough to earn a click.

LinkedIn advertising enables persona-level content delivery. Because LinkedIn allows targeting by title, function, and seniority at specified companies, it is the channel best suited to running parallel content tracks to different buying committee members simultaneously. A MOFU white paper on trial design strategy goes to Clinical Program Directors and VPs of Clinical Development at target accounts. A vendor qualification resource goes to Procurement and Operations titles at the same accounts. Each persona sees content calibrated to their role, served in a professional context where they are already in a relevant mindset. An additional consideration here is that LinkedIn ad pricing tends to run expensive, so LinkedIn targeting should be focused on key targets and personas and lead to high value content.

Contact-level advertising takes this precision one step further: rather than targeting a title category, content is served to specific named individuals on the buying committee contact list. As discussed in the previous post in this series on contact-level account-based marketing, this approach requires a well-constructed contact list but produces individually attributable engagement data — you know not just that someone with a procurement title engaged with vendor qualification content, but which specific person did.

Email nurture sequences are the primary vehicle for MOFU and BOFU content delivery to contacts already in the CRM. A well-structured email nurture sequence in life sciences ABM is not a generic drip campaign, it is a sequenced series of content offers calibrated to the recipient's role and the account's current position in the funnel, based on what they have already engaged with. If the Clinical Program Director at a priority account downloaded a Phase 2 design guide last month, the next email to that contact should not offer them an introductory blog post — it should offer them a case study on Phase 2 execution that builds on what they have already signaled interest in.

Live webinars and virtual events are among the highest-signal content formats available in life sciences ABM, and consistently underutilized. A webinar on a technically substantive topic — biomarker strategy in oncology, analytical challenges in cell therapy manufacturing, regulatory considerations for complex biologics — attracts registrants who are genuinely working on that problem. Every registration generates an individually identified data point: name, title, company, email. Attendance at the live event, engagement with Q&A, and post-event content downloads all add layers of signal that reveal the depth of interest and the likelihood of active buying intent.

The strategic value of webinars in ABM is not just the leads they generate directly. It is the buying group intelligence they produce. When three people with different titles from the same target account attend a webinar, that is a buying group signal that should immediately elevate that account in the scoring system and trigger targeted outreach.

Reading the Pattern: From Content Engagement to Buying Group Identification

Individual content engagement events provide data points. Patterns of engagement across multiple individuals at the same account, across multiple content formats, within a defined timeframe build these data points into a picture of an in-market buying group.

The pattern to look for is multi-persona, multi-touchpoint engagement - and ideally concentrated within a short window. A single scientist downloading a white paper is interesting. A Clinical Program Director, a Biomarker Scientist, and a Procurement Manager from the same biotech all engaging with MOFU content within a two-week period is a strong signal that something is being evaluated. If that account has also recently filed a new clinical trial registration (data that can be gathered via layering in the structural signals discussed in the previous post on life science intent) the cumulative signal becomes even stronger.

This is the moment that separates ABM programs that generate engagement data from ones that generate pipeline. The account should be elevated immediately. The buying committee contact list should be reviewed and updated. Contact-level advertising, if available, should be running to key individuals at that account. And the SDR or BD team should be initiating outreach using a targeted, contextually informed conversation that opens by referencing the specific topics that individuals at the account have been engaging with.

The content didn't just attract a lead. It surfaced a buying group, identified the individuals in it, revealed what they are working on, and created the conditions for a commercial conversation that is already relevant before it begins. That is what content as a compass actually means in practice, and it is the standard that a well-designed life sciences ABM content program should be held to.

A Note on Content Quality and Credibility

Everything described in this post depends on one foundational requirement: the content has to be genuinely good.

Life science buyers are trained evaluators. They will read a white paper and know within the first two pages whether it reflects real expertise or surface-level familiarity with the topic. They will attend a webinar and assess immediately whether the presenter understands the nuances of the problem being discussed. Content that fails this test does not just fail to generate engagement, it actively damages the credibility it was meant to build.

The investment required to produce technically credible, scientifically substantive content for a life science audience is not trivial. It requires either deep internal subject matter expertise or an external partner who genuinely understands the science and the commercial context in which it operates. That investment is not optional. It is the prerequisite on which every other element of a content-driven ABM program depends.

Finding Intent Signals in B2B Life Sciences Account-Based Marketing

Intent data is one of the most powerful concepts in modern B2B marketing. The idea is straightforward: if you can identify which companies are actively researching a problem your solution solves, you can focus your commercial resources on those accounts at precisely the moment they are most likely to buy. Done well, it transforms prospecting from an exercise in educated guessing into something far more precise. This targeted marketing is a core concept of account-based marketing (ABM.)

The challenge for life science companies is that the intent data infrastructure built to support ABM programs was designed almost entirely for the B2B technology sector. The signals it captures, the databases it monitors, and the models it uses to score account intent are calibrated for software buyers — not for the biotech, pharma, and research institutions that make up the life science market. For organizations in this sector, adopting standard ABM intent tooling without adaptation produces a program that is technically sophisticated but commercially misaligned — surfacing the wrong accounts, missing the right ones, and generating noise rather than intelligence.

This post explains what genuine intent looks like in B2B life sciences, why standard ABM platforms are limited in capturing it, and how to build an intent intelligence approach that reflects the actual dynamics of this market.

What Standard ABM Intent Data Actually Measures

To understand why standard intent tools underperform in life sciences, it helps to understand what they are actually measuring.

The major ABM intent platforms — Bombora, 6Sense, Demandbase, Propensity, and others — build their intent models primarily around two types of signal. The first is keyword-based web activity: elevated volumes of search queries and content consumption around specific topics, detected through publisher networks, content partnerships, and search engine data. When an unusual number of employees at a company are searching for terms associated with your solution category — "clinical data management software," "CRO selection," "bioanalytical outsourcing" — the platform flags that company as showing elevated intent.

The fundamental limitation of keyword-based web activity in the life science sector is the granularity required to isolate meaningful commercial signals. When monitoring broad technical terms—such as specific assay types—the resulting data frequently conflates scientists seeking protocol guidance with stakeholders intending to outsource the work. Consequently, relying on standard keyword models often produces a frustrating mix of missed opportunities and false positives, requiring a level of specificity that most generic platforms are unequipped to handle.

The second type of intent data is behavioral pattern matching: tracking when company employees visit competitor websites, engage with industry analyst reports, or interact with solution-category content in ways that suggest an active evaluation is underway.

These signals are genuinely useful in the B2B technology market, where buyers research solutions primarily through web searches, vendor websites, and analyst coverage before initiating contact. When a team is evaluating a new CRM, they search, they compare, they read G2 reviews, and they visit vendor sites. That behavior is detectable and meaningful.

In life sciences, this behavioral pattern either does not exist in the same form, or when it does, it is a lagging indicator rather than a leading one. A biotech that has already decided to outsource its Phase 2 biomarker program and is now requesting proposals is generating keyword intent signals — but by the time those signals are detectable, the evaluation is likely already underway and the vendor shortlist may already be forming. The most valuable moment to reach that account was weeks or months earlier, when the decision to advance the program was made but the vendor selection process had not yet begun.

Standard ABM tools are not designed to surface that earlier signal. They are designed to detect the behavioral footprint of an active search — which in life sciences arrives too late to provide maximum commercial advantage.

What Genuine Intent Looks Like in Life Sciences

The most predictive intent signals in B2B life sciences are not behavioral patterns detected through web monitoring. They are discoverable events — publicly documented milestones in a company's scientific, clinical, and financial development that predictably precede the formation of a buying group around specific vendor needs.

These events are explicit, time-stamped, and available through public data sources. They do not require inference or probabilistic scoring. When they occur, the commercial implication is usually clear.

Clinical trial registrations and IND filings are among the most valuable signals available. A new ClinicalTrials.gov registration indicates that a specific program has been designed, approved for execution, and is preparing to enroll. An IND submission signals that a company is preparing to advance an asset into first-in-human studies. Both events create immediate and specific purchasing needs: clinical operations support, central laboratory services, bioanalytical and biomarker capabilities, regulatory affairs support, and more. The program is defined, the timeline is beginning, and the buying group is forming. Vendors who identify this signal early and engage the relevant personas before the RFP process begins have a meaningful advantage over those who wait to be invited.

Funding events — Series B, C, and D rounds, IPOs, and significant non-dilutive funding such as BARDA contracts or large NIH grants — are direct predictors of program acceleration and vendor investment. Funding does not just provide capital; it creates organizational pressure to deploy that capital productively and to demonstrate progress against the milestones used to justify the raise. The months following a significant funding event are among the most commercially active periods in a biotech's lifecycle. A company that raised a $120M Series C to advance two assets into Phase 2 is not a prospect to put in a nurture sequence — it is an account to engage immediately and aggressively.

Regulatory milestones compress timelines and create urgency. A Fast Track designation, a Breakthrough Therapy designation, an Orphan Drug designation, or a Priority Review designation all signal that the FDA has recognized the potential significance of an asset and is providing mechanisms to accelerate its development. For vendors serving the clinical development pipeline, these designations are a direct signal that the program in question is being resourced and accelerated — and that the buying group associated with it is likely to make decisions faster than a standard development timeline would suggest.

Pipeline advancement events — a company announcing positive Phase 1 data, a transition from preclinical to IND-enabling studies, or a decision to advance an asset from Phase 2 into a pivotal trial — each carry specific and predictable commercial implications. The services and technologies needed at Phase 2 are different from those needed at Phase 1, and the investment required for a pivotal trial is substantially larger. These transitions create new buying groups, new budget allocations, and new vendor needs that did not exist at the prior stage.

Partnerships, licensing deals, and acquisitions can signal both program advancement and organizational transformation. A licensing deal that brings a new asset into a company's pipeline creates immediate needs around program support infrastructure. An acquisition can introduce new therapeutic capabilities and create demand for the vendor relationships needed to support them. Large co-development partnerships with major pharma often trigger significant investment in outsourced services to support the partnered program.

For academic and government research targets, grant award databases — NIH Reporter, BARDA contract awards, DOD funding announcements — are the equivalent signals. A new R01 award to a research group working in a relevant therapeutic area is a direct indicator of funded research activity and the instrument and reagent purchasing that will follow.

Why a Layered Intelligence Approach Outperforms Single-Source Intent

The strongest life science ABM programs do not rely on a single source of intent intelligence. They layer multiple signal types to create a picture of in-market accounts that is both strategically grounded and behaviorally confirmed.

The foundation layer is the public events described above: clinical trial filings, funding rounds, regulatory designations, pipeline transitions. These signals establish that an account has a documentable reason to be in market. They are captured through dedicated life-science data platforms — clinical trial registries, SEC and regulatory filing databases, pipeline intelligence services, and grant award databases — rather than through standard ABM intent platforms.

The second layer is keyword-based behavioral intent, sourced from standard ABM platforms. While this signal type is less predictive in isolation for life science accounts, it remains useful as a corroborating indicator. An account that has recently filed a new IND and shows elevated web activity around relevant search terms is a stronger signal than either data point alone. When event-driven and behavioral intent converge on the same account, the probability of active buying-cycle engagement is significantly higher.

The third layer is first-party engagement data from your own campaigns: website visits, content downloads, webinar registrations, ad interactions, and email engagement. An account that appears in your event-driven intent data, is showing behavioral intent signals in the broader web environment, and has had multiple individuals engage with your own content is an account where a buying group may already be forming. This is the account that should be at the top of your SDR priority list — not because of probabilistic scoring, but because three distinct types of evidence are pointing in the same direction.

From Intent Signal to Commercial Action

Identifying intent signals is only the first step. The commercial value is realized in how quickly and precisely the organization responds to them.

When a target account generates a meaningful intent signal — a new clinical trial registration, a funding round, a regulatory designation — the ideal commercial response is not to add that account to a generic nurture sequence. It is to elevate that account immediately in an ABM program's tier structure, identify or update the buying committee contact list for that account, ensure that contact-level or persona-level advertising is running to the relevant individuals, and — for the highest-priority accounts — trigger targeted outreach from the BD or SDR team within days rather than weeks.

The speed of response matters more in life sciences than most commercial teams appreciate. Buying groups form, make shortlists, and issue RFPs on timelines driven by their program milestones, not by the vendor's campaign calendar. An organization that identifies the intent signal and engages within the first week of a new clinical trial filing is having a different conversation than one that engages two months later when the RFP has already been issued. The window of maximum commercial advantage is real — and it closes.

This is what separates a life science ABM program built on the right intent intelligence from one built on generic tools: not just better targeting, but the ability to act at the right moment, with the right message, to the right people — before the buying process has already decided who is in the room.

Contact-Level ABM: Targeting the Key Individuals Within Accounts 

Most ABM programs target accounts. The best ABM programs target people.

This distinction sounds subtle, but its commercial implications are significant. Account-level targeting — serving ads to all employees at a specified set of companies — is a meaningful improvement over broadcasting to the open market. But it still leaves a gap between the audience your budget is reaching and the audience that actually matters for a deal. Contact-level ABM closes that gap.

This post explains what contact-level ABM is, why it represents a genuine upgrade in precision over standard account-level targeting, and which tools are enabling it in B2B life sciences today.

The Limitation of Account-Level Targeting

When a standard ABM program runs programmatic display advertising to a target account list, the targeting mechanism works at the domain or IP address level. The platform identifies devices associated with the target company's network and serves ads to them. In practice, this means your ads are being seen by a broad cross-section of that organization — finance staff, HR, IT, facilities, legal — the vast majority of whom have no relevance to your solution.

Even layering in title or function targeting on LinkedIn, which significantly improves precision, is an approximation. Targeting "Senior Directors and above in Clinical Operations at your target account list" will reach a useful audience, but it will also include people adjacent to the buying committee, exclude buying committee members with non-standard titles, and provide no visibility into which specific individuals are engaging.

Therefore, if you know specific people to target at an account, using broad level account targeting is inefficient. You end up with significant ad spend reaching large numbers of people who will never influence a purchasing decision, while the specific individuals who will are reached only intermittently and without the individual-level visibility that would make outreach actionable.

Account-level targeting is not without value — it builds brand familiarity across an organization, which has genuine commercial benefit. But for the highest-priority accounts and personas, it limits the ability to prioritize getting in front of the right people.

What Contact-Level ABM Does Differently

Contact-level ABM operates from a fundamentally different starting point: instead of targeting a domain or an IP range, it targets a curated list of specific, named individuals.

Using email addresses, names, or device ID matching, contact-level ABM platforms serve ads directly to identified individuals — the exact people you have determined are most likely to be members of the buying committee at your target accounts. Your budget in contact-level ABM is spent almost entirely on those specific people, rather than on the broader organizational population.

The precision has two important consequences.

First, efficiency improves dramatically. When your advertising reaches a list of 200 named individuals across 40 target accounts - those most likely to be part of buying groups - every impression has much higher relevance. There is limited waste of the kind built into account-level programmatic targeting.

Second, and more importantly for the commercial team, the engagement data becomes individually actionable. In account-level ABM, you might know that three people at a target biotech have clicked on your ads this month — but you may not know who they are, what their roles are, or whether they may be part of an-market buying group. In contact-level ABM, you know that the VP of Translational Medicine clicked twice, the Clinical Program Director clicked four times and visited the content page, and the Head of Procurement opened the email sequence. That is a buying committee picture, not an account-level signal — and it significantly changes how the sales team is empowered to engage with a target account.

How Contact-Level Targeting Works

Contact-level ABM platforms work by matching the contacts on your list to real, observable individuals as they browse the web. When a contact on your list visits a property within the platform's publisher network, the platform recognizes them — through email address matching, device ID resolution, or identity graph lookups — and serves your ad to that specific person. The matching happens behind the scenes; from the contact's perspective, they simply see a relevant ad while going about their normal browsing behavior.

Because recognition and serving happen at the individual level, the engagement data the platform returns is correspondingly granular. Marketers and SDRs can see, for each specific contact, how many impressions they received, which ads they engaged with, what content they interacted with downstream, and how their engagement has trended over time. That individual-level record is what makes contact-level ABM commercially actionable in a way that account-level targeting cannot match.

The practical implication for the sales team is significant. Instead of receiving a notification that "someone at Acme Biotech has been active this week" and having to investigate who that might be, the SDR receives a ranked list of named individuals — with titles, content histories, and engagement frequencies — that tells them precisely who to call, in what order, and what to reference when they do. The quality of that first outreach conversation improves substantially when it can open with specific relevance rather than a generic pitch.

Contact-level platforms also integrate with CRM and marketing automation systems, meaning engagement signals flow automatically into the tools the commercial team is already using. A contact who crosses a defined engagement threshold can trigger an SDR task, a lead score update, or an account elevation — without requiring manual review of campaign data. The system surfaces the signal; the team acts on it.

Building the Right Contact List: Where the Real Work Happens

Contact-level targeting is only as powerful as the list it operates from. Precision targeting of the wrong people produces precise data about irrelevant engagement. The effort invested in constructing a high-quality contact list is what determines whether a contact-level ABM program generates genuine commercial intelligence or merely impressive-looking metrics.

In life sciences, building that list well requires assembling intelligence from several distinct sources and using each to inform the others.

1. Start with Life-Science-Specific Intent Signals to Identify the Right Accounts

Before identifying specific contacts, the first question is: which accounts are most likely to be in an active buying cycle right now? In life sciences, the answer comes not from keyword-based web intent data — the signal type that general-purpose ABM platforms are built around — but from events that are predictive of near-term purchasing need.

A new clinical trial registration indicates that a specific program is advancing and that buying groups are likely forming around the services and capabilities needed to execute it. An IND filing signals that a program is preparing for first-in-human work, with all the operational and scientific purchasing that entails. A Series C or D funding round almost always precedes acceleration of program investment and vendor engagement. A regulatory designation — Fast Track, Breakthrough Therapy, Orphan Drug — compresses timelines and creates urgent purchasing needs. A new partnership or licensing deal may bring capital and new program activity simultaneously.

These events are publicly available and systematically trackable through clinical trial registries, regulatory submission databases, SEC filings, and life-science-specific pipeline intelligence platforms. Organizations that build their target account lists from these signals — rather than from generic web intent data — are starting from a fundamentally stronger intelligence position. The accounts they target are not just companies that look like good fits on paper; they are companies with a demonstrable, time-stamped reason to be in-market for a relevant solution.

2. Map the Right Personas for Each Account Type

With a target account list grounded in life-science-specific intent, the next step is determining which individuals within those accounts belong on the contact list. This is where persona mapping does its most important work.

A well-constructed persona map for a given ICP segment documents the titles, functions, and seniority levels that typically appear on the buying committee for that type of purchase. It is built from commercial experience — the sales and BD team's accumulated knowledge of who is actually present when deals of a given type get evaluated and closed — and validated against known patterns in the target account type.

The persona map translates directly into search criteria: when using a contact database to find individuals at a target account, you are looking for the specific titles and functions identified in the persona map. A precise persona map produces a precise contact list. A vague one — "senior people in clinical" — produces a list that is too broad to be useful for contact-level targeting.

The persona map should also be differentiated by account type. The buying committee for a large pharma account and the buying committee for a Series B biotech may share some common roles but differ significantly in seniority, organizational structure, and the degree to which functions are centralized or distributed across programs.

3. Use Contact Databases to Find the Named Individuals

With target accounts identified through intent signals and target personas defined through the persona map, the final step in list construction is finding the specific named individuals who hold those roles at those accounts.

B2B contact databases — platforms that aggregate professional profile data including name, title, employer, email address, and seniority level — are the primary tool for this work. For life sciences, databases with strong coverage of the biotech and pharma sectors, regularly refreshed to account for the high rate of organizational change in this industry, are essential. A contact list built from data that is twelve months out of date in an environment where companies routinely restructure, merge, or reduce headcount is a list that will underperform.

The database search takes the persona map as its input and returns a set of matching individuals at each target account. That set is then cross-referenced with CRM contacts — elevating anyone the commercial team has already engaged — and supplemented with prior campaign engagement data and sales team intelligence from conferences and prior business development activity.

The resulting contact list is not a generic prospecting database. It is a curated set of individuals who work at accounts with documented reasons to be in-market, in roles that correspond to the buying committee for your specific solution type. That specificity is what makes contact-level ABM generate the kind of engagement data that actually moves pipeline.